Compare OPBK & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | ENLV |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 258.7M |
| IPO Year | 2018 | 2014 |
| Metric | OPBK | ENLV |
|---|---|---|
| Price | $14.25 | $0.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $16.50 | ★ $20.00 |
| AVG Volume (30 Days) | 35.5K | ★ 756.6K |
| Earning Date | 04-23-2026 | 05-29-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 23.74 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $3,204,000.00 | N/A |
| Revenue This Year | $16.07 | N/A |
| Revenue Next Year | $11.60 | N/A |
| P/E Ratio | $8.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.03 | $0.66 |
| 52 Week High | $15.27 | $2.10 |
| Indicator | OPBK | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 37.33 |
| Support Level | $13.81 | $0.81 |
| Resistance Level | $14.71 | $1.19 |
| Average True Range (ATR) | 0.30 | 0.11 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 88.24 | 13.06 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.